NEOGENOMICS INC (NEO) FY2025 10-K Annual Report
NEOGENOMICS INC (NEO) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 17, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
NEOGENOMICS INC FY2025 10-K Analysis
Business Overview
- • Core business: oncology-focused diagnostic testing and consultative services, including molecular and precision cancer testing
- • Emphasis on growth in therapy selection and Molecular Residual Disease (MRD) testing with launches under a 2026 launch excellence program
Management Discussion & Analysis
- • Revenue $727.3M in 2025, up 10.1% YoY or $66.8M, driven by higher test volumes, higher value tests, reimbursement, and Pathline acquisition
- • Gross profit $314.3M, margin 43.2% in 2025 vs 43.9% in 2024, a 0.7% margin decline mainly from Pathline acquisition and rising costs
Risk Factors
- • FDA potential regulation of Laboratory Developed Tests requiring clinical trials and approvals, risking operational disruptions and costs
- • Global conflicts and political unrest posing business disruption risks with no specific regional revenue exposure disclosed
NEOGENOMICS INC FY2025 Key Financial MetricsXBRL
Revenue
$727M
▲ +10.1% YoY
Net Income
-$108M
▼ -37.2% YoY
Gross Margin
43.2%
▼ -71bp YoY
Operating Margin
-15.9%
▼ -199bp YoY
Net Margin
-14.9%
▼ -293bp YoY
ROE
-12.9%
▼ -419bp YoY
Total Assets
$1.4B
▼ -17.0% YoY
Operating Cash Flow
$5M
▼ -25.5% YoY
Source: XBRL data from NEOGENOMICS INC FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on NEOGENOMICS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.